[go: up one dir, main page]

AU2002255263A1 - Novel 1H-indazole compound - Google Patents

Novel 1H-indazole compound

Info

Publication number
AU2002255263A1
AU2002255263A1 AU2002255263A AU2002255263A AU2002255263A1 AU 2002255263 A1 AU2002255263 A1 AU 2002255263A1 AU 2002255263 A AU2002255263 A AU 2002255263A AU 2002255263 A AU2002255263 A AU 2002255263A AU 2002255263 A1 AU2002255263 A1 AU 2002255263A1
Authority
AU
Australia
Prior art keywords
novel
indazole compound
indazole
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002255263A
Other versions
AU2002255263B2 (en
Inventor
Takashi Doko
Naohiro Kohmura
Norihito Ohi
Hitoshi Oinuma
Nobuaki Sato
Hidenori Seshimo
Motohiro Soejima
Taro Terauchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority claimed from PCT/JP2002/003735 external-priority patent/WO2002083648A1/en
Publication of AU2002255263A1 publication Critical patent/AU2002255263A1/en
Application granted granted Critical
Publication of AU2002255263B2 publication Critical patent/AU2002255263B2/en
Assigned to EISAI R&D MANAGEMENT CO., LTD. reassignment EISAI R&D MANAGEMENT CO., LTD. Request for Assignment Assignors: EISAI CO., LTD.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002255263A 2001-04-16 2002-04-15 Novel 1H-indazole compound Ceased AU2002255263B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-116521 2001-04-16
JP2001116521 2001-04-16
PCT/JP2002/003735 WO2002083648A1 (en) 2001-04-16 2002-04-15 Novel 1h-indazole compound

Publications (2)

Publication Number Publication Date
AU2002255263A1 true AU2002255263A1 (en) 2003-04-17
AU2002255263B2 AU2002255263B2 (en) 2006-12-14

Family

ID=18967246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002255263A Ceased AU2002255263B2 (en) 2001-04-16 2002-04-15 Novel 1H-indazole compound

Country Status (10)

Country Link
US (3) US6982274B2 (en)
EP (1) EP1380576B1 (en)
JP (1) JP4535680B2 (en)
KR (1) KR20040007497A (en)
CN (1) CN1300116C (en)
AT (1) ATE449763T1 (en)
AU (1) AU2002255263B2 (en)
CA (1) CA2440842A1 (en)
DE (1) DE60234510D1 (en)
WO (1) WO2002083648A1 (en)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
US6982274B2 (en) * 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
WO2003072550A1 (en) 2002-02-28 2003-09-04 Eisai Co., Ltd. Novel fused ring indazole compounds
FR2836914B1 (en) * 2002-03-11 2008-03-14 Aventis Pharma Sa SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
WO2004014368A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
AU2003286711A1 (en) * 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
CA2521907A1 (en) * 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US7560467B2 (en) 2003-06-19 2009-07-14 Smithkline Beecham Corporation Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors
SE0301906D0 (en) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
ATE553092T1 (en) * 2003-07-30 2012-04-15 Kyowa Hakko Kirin Co Ltd INDAZOLE DERIVATIVES
CA2518951A1 (en) * 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitors
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
CA2539549A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
WO2005035516A1 (en) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
US20060004043A1 (en) * 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
ES2338060T3 (en) 2003-12-22 2010-05-03 Basilea Pharmaceutica Ag ARILOXI AND ARILTOXIA-CETOPHENONE TYPE COMPONENTS FOR CANCER TREATMENT.
JP2007520471A (en) * 2003-12-22 2007-07-26 イーライ リリー アンド カンパニー Bicyclic derivatives as PPAR receptor modulators
WO2005085206A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
US7378532B2 (en) 2004-03-26 2008-05-27 Yung Shin Pharmaceutical Ind. Co., Ltd. Fused pyrazolyl compound
GB0409080D0 (en) * 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
WO2006015124A2 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
JPWO2006080450A1 (en) * 2005-01-27 2008-06-19 協和醗酵工業株式会社 IGF-1R inhibitor
US7291614B2 (en) * 2005-02-24 2007-11-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
WO2007097937A1 (en) * 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as erk inhibitors
WO2007126964A2 (en) * 2006-03-31 2007-11-08 Schering Corporation Kinase inhibitors
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP3091011B1 (en) 2006-04-07 2017-12-27 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20120329794A1 (en) 2006-06-30 2012-12-27 Kyowa Hakko Kirin Co., Ltd. Ab1 KINASE INHIBITORS
EP2036894A4 (en) * 2006-06-30 2011-01-12 Kyowa Hakko Kirin Co Ltd Aurora inhibitor
DE102006030479A1 (en) * 2006-07-01 2008-03-20 Merck Patent Gmbh indazole
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008061109A2 (en) * 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
JP2010513495A (en) * 2006-12-20 2010-04-30 シェーリング コーポレイション Novel JNK inhibitor
CN101611007A (en) 2006-12-20 2009-12-23 先灵公司 Novel JNK Inhibitors
KR20090115866A (en) 2007-03-05 2009-11-09 교와 핫꼬 기린 가부시키가이샤 Medicinal composition
DE102007028521A1 (en) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (en) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
US7919581B2 (en) 2007-07-31 2011-04-05 Burnham Institute For Medical Research Bi-dentate compounds as kinase inhibitors
DK2178870T3 (en) 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
DE102007041116A1 (en) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-dihydro-isoindole derivatives
WO2009105500A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
EP2323989A4 (en) * 2008-03-20 2011-06-22 Abbott Lab Methods for making central nervous system agents that are trpv1 antagonists
DE102008061214A1 (en) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
ES2660892T3 (en) * 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for pain management
DE102009054302A1 (en) 2009-11-23 2011-05-26 Merck Patent Gmbh quinazoline derivatives
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG10201505700QA (en) 2010-04-22 2015-08-28 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
US8999957B2 (en) * 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012015932A2 (en) * 2010-07-27 2012-02-02 Protexer, Inc. Shoe cover removal apparatus
EP2613782B1 (en) * 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
MX347889B (en) 2010-09-03 2017-05-17 Forma Tm Llc * Novel compounds and compositions for the inhibition of nampt.
DE102010046837A1 (en) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
WO2012078777A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
EP2654748B1 (en) * 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012129338A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
EP2766352B1 (en) * 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101511771B1 (en) * 2011-12-20 2015-04-14 주식회사 엘지생명과학 Indole and indazole compounds as an inhibitor of cellular necrosis
JP6157455B2 (en) 2012-04-25 2017-07-05 武田薬品工業株式会社 Nitrogen-containing heterocyclic compounds
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
US8980934B2 (en) 2012-06-22 2015-03-17 University Health Network Kinase inhibitors and method of treating cancer with same
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
AR092857A1 (en) 2012-07-16 2015-05-06 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF (R) -1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) -N- (1- (2,3-DIHYDROXIPROPIL) -6-FLUORO-2- ( 1-HYDROXI-2-METHYLPROPAN-2-IL) -1H-INDOL-5-IL) CYCLOPROPANCARBOXAMIDE AND ADMINISTRATION OF THE SAME
TW201427970A (en) * 2012-10-12 2014-07-16 Univ Health Network Kinase inhibitors and method of treating cancer with same
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137728A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014142255A1 (en) 2013-03-14 2014-09-18 武田薬品工業株式会社 Heterocyclic compound
LT2986610T (en) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
JP6427491B2 (en) 2013-07-03 2018-11-21 武田薬品工業株式会社 Heterocyclic compounds
JP6411342B2 (en) 2013-07-03 2018-10-24 武田薬品工業株式会社 Amide compounds
WO2015015519A1 (en) 2013-07-31 2015-02-05 Council Of Scientific & Industrial Research Novel indazole compounds and a process for the preparation thereof
US10351527B2 (en) 2014-04-09 2019-07-16 The University Of British Columbia Binding function 3 (BF3) site compounds as therapeutics and methods for their use
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
CN105061316B (en) * 2015-07-17 2017-12-22 苏州大学 Thick cyclics, preparation method and purposes
AU2015406253B2 (en) * 2015-08-20 2021-02-25 Js Innopharm (Shanghai) Ltd. Pyrazolo fused heterocyclic compounds as ERK inhibitors
KR102484810B1 (en) * 2016-05-25 2023-01-05 (주)아모레퍼시픽 Skin brightening composition
EP3584241B1 (en) * 2017-02-14 2023-04-26 FUJIFILM Corporation Method for producing indazole compound, and indazole compound
CN108727340B (en) * 2017-04-11 2020-12-29 广东东阳光药业有限公司 Fluorine-substituted indazoles and their uses
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2018234354A1 (en) * 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
WO2018234353A1 (en) * 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE
KR20190043437A (en) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 Heterocylic compound as a protein kinase inhibitor
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
KR102195348B1 (en) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 Novel compound as a protein kinase inhibitor, and the pharmaceutical composition comprising thereof
CN114040760B (en) 2018-12-31 2025-05-09 拜欧米富士恩公司 Irreversible inhibitors of MENIN-MLL interactions
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12448375B2 (en) 2019-09-11 2025-10-21 Ohio State Innovation Foundation Kinase inhibitors for the treatment of neurodegenerative diseases
WO2021067374A1 (en) * 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (en) 2019-10-14 2022-10-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022147246A1 (en) 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126101A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
JP2024534014A (en) 2021-08-20 2024-09-18 バイオメア フュージョン，インコーポレイテッド Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-MLL inhibitor for the treatment of cancer
CN113999211B (en) * 2021-11-23 2022-11-29 郑州大学 Indazole skeleton derivative containing 1,2,3-triazole with specific activity of resisting prostate cancer
IL321498A (en) * 2022-12-16 2025-08-01 Certa Therapeutics Pty Ltd Heterocyclic compounds and uses thereof
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN118994130A (en) * 2024-07-02 2024-11-22 中国药科大学 Indazole amide compound and application thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1266763B (en) * 1965-07-27 1968-04-25 Kalle Ag Process for the preparation of indole and indazole derivatives substituted in the 3-position
JPS5944314B2 (en) 1975-01-15 1984-10-29 中外製薬株式会社 Manufacturing method of indazole derivatives
JPS604824B2 (en) 1976-04-02 1985-02-06 中外製薬株式会社 Indazole derivative
JPS5615287A (en) 1979-07-16 1981-02-14 Chugai Pharmaceut Co Ltd Pyrazoloindazole derivative and its preparation
JPH01180878A (en) 1988-01-11 1989-07-18 Yoshitomi Pharmaceut Ind Ltd Condensed pyrazole compound
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
GB8811299D0 (en) 1988-05-12 1988-06-15 Grayshan R Indazole derivatives
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
US5051430A (en) * 1990-09-10 1991-09-24 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1H-indazol-3-yl)-4-pyridinamines
JPH06206872A (en) 1992-10-06 1994-07-26 Yoshitomi Pharmaceut Ind Ltd Condensed type pyrazole compound
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AU1345697A (en) 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
BR9712782A (en) * 1996-06-25 1999-12-07 Pfizer Substituted indazole derivatives and their use as inhibitors of phosphodiesterosis (pde) and tumor necrosis factor (tnf)
CZ20001621A3 (en) * 1997-11-04 2001-08-15 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
DE19821002A1 (en) * 1998-05-11 1999-11-18 Dresden Arzneimittel New indazole derivatives useful as antiasthmatic, antiallergic, neuroprotective agents and for treatment of inflammation and immune disorders
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
EP1091960A1 (en) 1998-06-29 2001-04-18 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
ATE252572T1 (en) 1998-06-30 2003-11-15 Lilly Co Eli 5-HT1F AGONISTS
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
EP1119568B1 (en) * 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
BR9916223A (en) 1998-12-17 2001-09-04 Hoffmann La Roche 4-aryloxindols as inhibitors of jnk protein kinases
BR9916272A (en) 1998-12-17 2001-09-04 Hoffmann La Roche 4 and 5-alkynyloxindols and 4 and 5-alkenyloxindols
CN1158283C (en) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 4-and 5-pyrazinyl oxindoles as protein kinase inhibitors
JP2000198734A (en) 1998-12-30 2000-07-18 Pfizer Inc Motility enhancers for the treatment of gastric motility impairment and related disorders
WO2000064872A1 (en) 1999-04-23 2000-11-02 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
CZ2002534A3 (en) * 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitors of protein-kinases, pharmaceutical preparations in which they are comprised as well as their use
CN1304375C (en) 1999-08-19 2007-03-14 信号药品公司 Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
JP4847662B2 (en) 1999-09-14 2011-12-28 アベンティスユービー・セカンド・インコーポレイテッド Thienoisoxazolyl- and thienylpyrazolyl-phenoxy-substituted propyl derivatives useful as D4 antagonists
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
YU54202A (en) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US6982274B2 (en) * 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound

Similar Documents

Publication Publication Date Title
AU2002255263A1 (en) Novel 1H-indazole compound
AU2002349297A1 (en) Statin-like compounds
AU2002360508A1 (en) Substituted hydroxyethylamines
GB0119467D0 (en) Novel compound
AU2002359165A1 (en) Novel compounds
AU2002359320A1 (en) Novel anit-infectives
AUPR878201A0 (en) New compounds
AUPR362001A0 (en) New compound
AU2002251024A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
AUPR409401A0 (en) Analgesic compound
WO2003016427A8 (en) Photoluminescent compounds
AU2002321215A1 (en) Substituted 4-aminocyclohexanols
AU2002228050A1 (en) Fungicidal mixtures
AUPR920301A0 (en) Neurologically-active compounds
AU2002339474A1 (en) Fungicidal mixtures
AU2002237275A1 (en) Fungicidal mixtures
AUPR336301A0 (en) New compound
AUPR336401A0 (en) New compound
AU2004201666B2 (en) 4-Imidazolin-2-one compounds
AUPR669701A0 (en) New compounds
AU2002255414A1 (en) New compounds
AUPR300701A0 (en) New compounds
HK1060725A (en) New compounds
AU2002316006A1 (en) New compounds
AUPR775701A0 (en) New compounds